Regulus Therapeutics' (RGLS) Abstract on RG-101 Not Presented at AASLD Conference

November 14, 2016 4:46 PM EST

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Regulus Therapeutics (NASDAQ: RGLS) said to withdraw abstract n RG-101, which was slated for presentation at AASLD last Saturday, according to Bloomberg.

Regulus' IND for RG-101 was placed on clinical hold in June.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Trader Talk

Add Your Comment